Carregant...
Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients
INTRODUCTION: Disease-modifying treatments for Alzheimer's disease (AD) are likely to be offered only to patients with molecular evidence for Alzheimer pathology and expanded to patients with prodromal AD. We calculated the potential future costs of expanding the number of positron emission tom...
Guardat en:
| Publicat a: | Alzheimers Dement (N Y) |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6709060/ https://ncbi.nlm.nih.gov/pubmed/31463360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2019.06.001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|